Regimen Improves PFS in Highly Mutated Metastatic Colorectal Cancer

(MedPage Today) — SAN FRANCISCO — Adding modified FOLFOX6 (oxaliplatin, leucovorin, and fluorouracil) and bevacizumab (Avastin) to atezolizumab (Tecentriq) significantly improved progression-free survival (PFS) in patients with previously untreated…